Literature DB >> 10878493

Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery.

G Falero-Diaz1, S Challacombe, D Rahman, M Mistry, G Douce, G Dougan, A Acosta, J Ivanyi.   

Abstract

BACKGROUND: The efficacy by which passive antibodies can reach the lungs could be important for the outcome of immunotherapy of respiratory pulmonary infections. We examined how transmission to a number of mucosal sites is affected by the route of inoculation.
METHODS: Transmission of newly raised IgA class Mabs against mycobacterial surface antigens to saliva, lung or vaginal lavage, bile and serum of BALB/c mice was compared with existing IgG Mabs. ELISA was used for testing body fluids obtained 1-24 h after intranasal or intravenous inoculation and 1-7 days following back-pack tumour growth of hybridomas.
RESULTS: Intranasal inoculation resulted in a rapid rise and high levels of both IgA and IgG class Mabs in lung lavage. In contrast, following intravenous Mab injection or back-pack tumour growth of hybridoma cells, effective lung transmission was observed for the IgG1 and IgG2b MAbs, but not for the IgA Mabs. The secretory component was acquired by the transmitted IgA MAbs in the mucosal fluids, but not in the serum. Nevertheless, the time course of mucosal IgA antibody levels was similar to that of the tested IgG Mabs. Furthermore, the relative proportion of transmission to saliva and bile varied between individual Mabs indicating a role of tissue-specific, immunoglobulin class-unrelated mechanisms.
CONCLUSIONS: Intranasal, rather than parenteral inoculation of mice is required for the efficient delivery of IgA antibodies against respiratory pulmonary pathogens. Interestingly, IgA-secretory component complexing of intranasally applied Mabs did not significantly influence their persistence in the lungs. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878493     DOI: 10.1159/000024370

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

Authors:  Ann Williams; Rajko Reljic; Irene Naylor; Simon O Clark; Gustavo Falero-Diaz; Mahavir Singh; Stephen Challacombe; Philip D Marsh; Juraj Ivanyi
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

2.  Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

Authors:  R Reljic; S O Clark; A Williams; G Falero-Diaz; M Singh; S Challacombe; P D Marsh; J Ivanyi
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

3.  Purification of an IgA Monoclonal Antibody Specific for the Acr Protein of Mycobacterium tuberculosis by Immunoaffinity Chromatography.

Authors:  Fátima Reyes; Oscar Otero; Frank Camacho; María Elena Sarmiento; Armando Acosta
Journal:  Malays J Med Sci       Date:  2013-10

4.  Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis.

Authors:  Natalie Zimmermann; Verena Thormann; Bo Hu; Anne-Britta Köhler; Aki Imai-Matsushima; Camille Locht; Eusondia Arnett; Larry S Schlesinger; Thomas Zoller; Mariana Schürmann; Stefan He Kaufmann; Hedda Wardemann
Journal:  EMBO Mol Med       Date:  2016-11-02       Impact factor: 12.137

Review 5.  The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.

Authors:  Sylvia Annabel Dass; Venugopal Balakrishnan; Norsyahida Arifin; Crystale Siew Ying Lim; Fazlina Nordin; Gee Jun Tye
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

6.  Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery.

Authors:  Ilaria Pepponi; Elena Stylianou; Craig van Dolleweerd; Gil Reynolds Diogo; Matthew J Paul; Pascal M W Drake; Julian K-C Ma; Rajko Reljic
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Evaluation of Humoral Immunity to Mycobacterium tuberculosis-Specific Antigens for Correlation with Clinical Status and Effective Vaccine Development.

Authors:  Mamiko Niki; Maho Suzukawa; Shunsuke Akashi; Hideaki Nagai; Ken Ohta; Manabu Inoue; Makoto Niki; Yukihiro Kaneko; Kozo Morimoto; Atsuyuki Kurashima; Seigo Kitada; Sohkichi Matsumoto; Koichi Suzuki; Yoshihiko Hoshino
Journal:  J Immunol Res       Date:  2015-10-19       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.